Home / Expertise / Intellectual Property / Patent Attorneys

Patent Attorneys

United Kingdom

The CMS patent attorney practice disrupts the traditional boutique approach to provide a service that meets the needs of modern business practice.  

Using proven, robust and efficient processes to manage portfolios through the patenting process, we pour care and attention into every detail, whether a portfolio’s value comes from its size or from the key nature of one or a small number of cases.

This is a people business, and we invest time in understanding the individuals we work with and their organisations.  Our clients’ patent portfolios are under constant scrutiny and clients’ need to know they are in the very best hands.  Our attorneys have long-held passions for the sectors we work in, with many having PhDs and / or industry experience in their chosen area. Always seeking to do things better, we have a culture of challenging each other and questioning how we work. This leads to constant improvements and the best solutions for each client.
 
Located as a part of a global law firm, we have immediate access to the broader legal perspective and an improved ability to understand and assess the risks associated with different strategies, further protecting our clients’ portfolios in the long term.

You can find out more about patent attorneys at CMS below:

 
Patent Attorney logo
 
About UsServicesPeople
Scientific ExpertiseBrexitCareers
 Contact Us 

 

Read more Read less

Feed

Show only
19 June 2020
CMS Pat­ent Team are re­com­men­ded in the IAM Pat­ent 1000, 2020 dir­ect­ory
CMS Pat­ent Team are re­com­men­ded in the IAM Pat­ent 1000, 2020 dir­ect­ory. Find out more.
26 June 2020
Court of Ap­peal re­fuses in­junc­tion in Neur­im v Mylan
We re­cently re­por­ted on the High Court judg­ment of Mr Justice Mar­cus Smith in Neur­im Phar­ma­ceut­ic­als (1991) Lim­ited and Flynn Pharma Lim­ited v Gen­er­ics UK Lim­ited (t/a Mylan) [2020] EWHC 1362 (Pat) in...
18 June 2020
CMS named amongst Fin­an­cial Times Europe’s lead­ing pat­ent law firms
CMS named amongst Fin­an­cial Times Europe’s lead­ing pat­ent law firms. Find out more.
23 June 2020
COV­ID-19 – UKIPO re­views and ends peri­od of ‘in­ter­rup­ted days’
The UKIPO has re­viewed the so-called peri­od of ‘in­ter­rup­ted days’ which star­ted on 24 March 2020 and de­cided that the last ‘in­ter­rup­ted day’ will be 29 Ju­ly 2020. An ‘in­ter­rup­ted day’ is defined...
28 April 2020
EPO Fee Changes 1 April 2020
EPO Fee Changes 1 April 2020 in­form­a­tion from the CMS Pat­ent At­tor­ney team. Find out more.
11 June 2020
Pat­ents Court re­fuses to grant in­ter­im in­junc­tion in phar­ma­ceut­ic­al pat­ents...
In a re­cent Pat­ents Court in­ter­im hear­ing con­cern­ing phar­ma­ceut­ic­al products, Mr Justice Mar­cus Smith re­fused an ap­plic­a­tion for an in­ter­im in­junc­tion. The judg­ment marks an ex­cep­tion to the “rule of...
2 October 2019
AI and per­son­al­ised medi­cine
Per­son­al­ised medi­cine at­tempts to de­term­ine the most ef­fect­ive treat­ment plan for a par­tic­u­lar in­di­vidu­al by com­bin­ing and ana­lys­ing in­form­a­tion from the pa­tient. The abil­ity of AI plat­forms to in­ter­rog­ate a wide range of in­form­a­tion has the po­ten­tial to
08 June 2020
Pat­ents Court Con­firms Onus to “Clear the Way” and Factors Giv­ing Rise...
Birss J has handed down an in­ter­im judg­ment in the Pat­ents Court which con­firms the ex­pect­a­tion on gen­er­ic phar­ma­ceut­ic­al com­pan­ies to “clear the way”, in ad­di­tion to factors which give rise to an...
24 September 2019
AI in dia­gnos­is – pat­ent pro­tec­tion
In this art­icle, we take a closer look at pat­ent pro­tec­tion in Europe for de­vel­op­ments of AI in dia­gnost­ic ap­plic­a­tions. There is enorm­ous po­ten­tial for the use of AI in dia­gnos­is and this is re­flec­ted in the in­creas­ing num­ber of reg­u­lat­ory ap­provals bein
03 June 2020
COV­ID-19 – UKIPO re­views and ex­tends peri­od of ‘in­ter­rup­ted days’
The UKIPO has re­viewed and again ex­ten­ded the so-called peri­od of ‘in­ter­rup­ted days’ which star­ted on 24 March 2020 to at least 22 June 2020. An ‘in­ter­rup­ted day’ is defined as “a day in which...
19 September 2019
AI & pa­tient com­pli­ance
This art­icle looks at tech­no­logy in the area of pa­tient com­pli­ance, an area where AI is hav­ing a huge im­pact on the life sci­ences in­dustry. Tech­no­lo­gies fa­cil­it­at­ing pa­tient com­pli­ance raise a host of in­tel­lec­tu­al prop­erty con­sid­er­a­tions in Europe.
01 June 2020
En­larged Board to cla­ri­fy European Pat­ent Of­fice ap­proach to double pat­ent­ing
The European Pat­ent Of­fice Tech­nic­al Board of Ap­peal has re­ferred three leg­al ques­tions to the En­larged Board of Ap­peal. These ques­tions con­cern the al­low­ab­il­ity of double pat­ent­ing at the EPO, and will...